6-Substituted 5-fluorouracil derivatives as transition state analogue inhibitors of thymidine phosphorylase

Nucleosides, Nucleotides and Nucleic Acids

Volumn 24, Issue 5-7, 2005, Pages 367-373

  Kalman, Thomas I ^a   Lai, Li ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' FLUORO 2' DEOXYURIDINE; 6 IMIDAZOLYLMETHYL 5 FLUOROURACIL; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL DERIVATIVE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME STRUCTURE; ESCHERICHIA COLI; INHIBITION KINETICS; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

BINDING SITES; ENZYME INHIBITORS; ESCHERICHIA COLI; FLUOROURACIL; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; PYRIMIDINES; THYMIDINE PHOSPHORYLASE;

ESCHERICHIA COLI;

EID: 26644453745     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1081/NCN-200059790     Document Type: Conference Paper

References (19)

1. Friedkin, M.; Roberts, D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J. Biol. Chem. 1954, 207(1), 245-256.
2. Brown, N.S.; Jones, A.; Fujiyama, C.; Harris, A.L.; Bicknell, R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000, 60, 6298-6302.
3. Langen, P.; Etzgold, G.; Bärwolff, D.; Preussel, B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem. Pharmacol. 1967, 16(9), 1833-1837.
4. Focher, F.; Ubiali, D.; Pregnolato, M.; Zhi, C.; Gambino, J.; Wright, G.E.; Spadari, S. Novel nonsubstrate inhibitors of human thymidine phosphorylase, a potential target for tumor-dependent angiogenesis. J. Med. Chem. 2000, 43, 2601-2607.
5. Klein, R.S.; Lenzi, M.; Lim, T.H.; Hotchkiss, K.A.; Wilson, P.; Schwartz, E.L. Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase. Biochem. Pharmacol. 2001, 62(9), 1257-1263.
6. Murray, P.E.; McNally, V.A.; Lockyer, S.D.; Williams, K.J.; Stratford, I.J.;Jaffar, M.; Freeman, S. Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase. Bioorg. Med. Chem. 2002, 10, 525-530.
7. Fukushima, M.; Suzuki, N.; Emura, T.; Yano, S.; Kazuno, H.; Tada, Y.; Yamada, Y.; Asao, T. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′- deoxyribonucleosides. Biochem. Pharmacol. 2000, 59(10), 1227-1236.
8. Cole, C.; Reigan, P.; Gbaj, A.; Edwards, P.N.; Douglas, K.T.; Stratford, I.J.; Freeman, S.; Jaffar, M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phoesphorylase. J. Med. Chem. 2003, 46, 207-209.
9. Balzarini, J.; Gamboa, A.E.; Esnouf, R.; Liekens, S.; Neyts, J.; De Clercq, E.; Camaraza, M.J.; Perez-Perez, M.J. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase. FEBS Lett. 1998, 438(1-2), 91-95.
10. Esteban-Gamboa, A.; Balzarini, J.; Esnouf, R.; De Clercq, E.; Camaraza, M.J.; Perez-Perez, M.J. Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase. J. Med. Chem. 2000, 43(5), 971-983.
11. Price, M.L.P.; Guida, W.C.; Jackson, T.E.; Nydick, J.A.; Gladstone, P.L.; Juarez, J.C.; Donate, F.; Ternansky, R.J. Design of novel N-(2,4-dioxo-1,2,3,4- tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model. Bioorg. Med. Chem. Lett. 2003, 13, 107-110.
12. Nakajima, Y.; Gotanda, T.; Uchimiya, H.; Furukawa, T.; Haraguchi, M.; Ikeda, R.; Sumizawa, T.; Yoshida, H.; Akiyama, S. Cancer Res. 2004, 64, 1794-1801.
13. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
14. Thorpe, P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 2004, 10(2), 415-427.
15. Pugmire, M.J.; Cook, W.J.; Jasanoff, A.; Walter, M.R.; Ealick, S.E. Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. J. Mol. Biol. 1998, 281, 285-299.
16. Schramm, V.L. Transition state analogues for enzymes of nucleic acid metabolism. Nucleic Acids Res., Suppl. 2003 (3), 107-108.
17. Birck, M.R.; Schramm, V.L. Nucleophilic participation in the transition state for human thymidine phosphorylase. J. Am. Chem. Soc. 2004, 126, 2447-2453.
18. Schwartz, M. Thymidine phosphorylase from Escherichia coli: properties and kinetics. Methods Enzymol. 1971, 51, 442-445.
19. Norman, R.A.; Barry, S.T.; Bate, M.; Breed, J.; Colls, J.D.; Emill, R.J.; Luke, R.W.A.; Minshull, C.A.; McAllister, M.S.B.; McCall, E.J.; McMiken, H.H.J.; Paterson, D.S.; Timms, D.; Tucker, J.A.; Pauptit, R.A. Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor. Structure 2004, 12, 75-84.